SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
CognitivePhase IVendors pending
Phase IVendors pendingFacts verified · 2026-05-25

BDNF

Also known as brain‑derived neurotrophic factor, neurotrophin, mbdnf, probdnf · Wikipedia

BDNF (Brain-Derived Neurotrophic Factor) is a 119-amino-acid mature neurotrophin protein, not a small peptide, cleaved from a 247-aa proBDNF precursor. It is central to neuroplasticity, learning and memory, and signals through the TrkB receptor. Altered BDNF signaling is implicated in depression, Alzheimer's, Huntington's, and other neurodegenerative and stress-related disorders. A critical bioavailability issue defines its research-channel use: peripheral recombinant BDNF does not meaningfully cross the blood-brain barrier, so vendor-sold injectable BDNF has very weak mechanistic justification for CNS effects and should be treated as low-evidence.

—

best

price

—

per

mg

—

vendors

tracked

Phase I

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

BDNF is a 119-amino-acid mature neurotrophin cleaved from a 247-aa proBDNF precursor; it is fundamentally a protein, not a short peptide. It signals through the TrkB receptor tyrosine kinase, activating Ras/MAPK, PI3K/Akt, and PLC-gamma pathways that drive neuronal survival, dendritic arborization, synaptogenesis, and long-term potentiation.

BDNF is a 119-amino-acid mature neurotrophin cleaved from a 247-aa proBDNF precursor; it is fundamentally a protein, not a short peptide. It signals through the TrkB receptor tyrosine kinase, activating Ras/MAPK, PI3K/Akt, and PLC-gamma pathways that drive neuronal survival, dendritic arborization, synaptogenesis, and long-term potentiation. Uncleaved proBDNF binds p75NTR with opposing pro-apoptotic effects, making the proBDNF:mBDNF ratio biologically consequential. Endogenous BDNF declines in depression and several neurodegenerative diseases (Bathina & Das, 2015, PubMed 26788077). Peripheral recombinant BDNF does not appreciably cross the BBB, which is why clinical CNS programs use AAV2-BDNF intraparenchymal gene therapy rather than systemic protein.

Pharmacokinetic properties

Half-life

Plasma half-life <10 minutes for recombinant BDNF (rapid proteolysis and clearance)

Routes

subcutaneous · intravenous · intranasal

Bioavailability

Critical bioavailability problem: BDNF does NOT meaningfully cross the blood-brain barrier after peripheral administration. Intranasal delivery achieves some nose-to-brain transport but quantitative CNS exposure is poorly characterized. Clinical trials for CNS indications use AAV gene therapy (e.g., AAV2-BDNF in early Alzheimer's), not peripheral recombinant protein, precisely because of BBB exclusion.

Amino-acid sequence

(Protein growth factor; mature human BDNF is 119 aa derived from proBDNF; full sequence omitted for brevity)

Use & research dosing

NeuroplasticityMemoryCognitive Support

There is no validated human dosing protocol for recombinant BDNF as a peripheral injectable. Research-channel material is sold in microgram quantities and any subcutaneous, intramuscular, or intranasal protocol is speculative because BBB exclusion makes a meaningful CNS effect from peripheral injection biologically implausible. Active CNS clinical programs (AAV2-BDNF in early Alzheimer's / MCI) deliver gene therapy intraparenchymally, not exogenous protein. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Major factual landmine: BDNF is a 119-amino-acid protein, not a small peptide, and peripheral recombinant BDNF does not meaningfully cross the blood-brain barrier. Vendors selling injectable BDNF for subcutaneous self-administration are offering a product with very weak mechanistic justification for CNS effects. Quality from research-grade sources is highly variable. Genuine CNS therapeutic programs use AAV gene therapy delivered directly to brain parenchyma.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Peripheral subcutaneous or intramuscular BDNF does not meaningfully cross the blood-brain barrier; efficacy claims for CNS effects via peripheral injection are not biologically well-supported
  • Recombinant protein folding and purity from research-grade sources are highly variable
  • Theoretical pain hypersensitization risk - BDNF mediates central and peripheral pain sensitization
  • TrkB signaling is implicated in some tumor biology - theoretical oncogenic concern
  • Not FDA-approved; no completed peripheral-administration human efficacy trials
  • Immunogenicity / anti-drug antibody risk with recombinant protein from unverified sources
  • Pregnancy and breastfeeding - safety unknown
  • Intranasal nose-to-brain transport is poorly quantified in humans

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/26788077/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/16884698/

Facts verified

2026-05-25

Confidence

low

What this means

  • protein-not-peptide
  • peripheral injection does not cross BBB
  • vendor-sold recombinant unlikely bioactive in CNS
  • no controlled human efficacy trials for peripheral administration

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.